Edgewise Therapeutics Inc (EWTX)
32.86
-0.40
(-1.20%)
USD |
NASDAQ |
Nov 14, 16:00
32.88
+0.02
(+0.06%)
After-Hours: 20:00
Edgewise Therapeutics Research and Development Expense (Quarterly): 30.68M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 30.68M |
| March 31, 2024 | 27.69M |
| December 31, 2023 | 27.68M |
| September 30, 2023 | 23.79M |
| June 30, 2023 | 19.56M |
| March 31, 2023 | 19.88M |
| December 31, 2022 | 16.61M |
| September 30, 2022 | 13.89M |
| June 30, 2022 | 12.40M |
| Date | Value |
|---|---|
| March 31, 2022 | 11.12M |
| December 31, 2021 | 9.088M |
| September 30, 2021 | 9.88M |
| June 30, 2021 | 7.861M |
| March 31, 2021 | 5.36M |
| December 31, 2020 | 5.139M |
| September 30, 2020 | 3.238M |
| June 30, 2020 | 3.639M |
| March 31, 2020 | 2.967M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.967M
Minimum
Mar 2020
30.68M
Maximum
Jun 2024
13.92M
Average
11.76M
Median
Research and Development Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 3.284M |
| Cytokinetics Inc | -- |
| Vanda Pharmaceuticals Inc | 16.66M |
| Vertex Pharmaceuticals Inc | 875.90M |
| Sarepta Therapeutics Inc | 224.48M |